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AMPA receptors (AMPARs) are tetrameric ligand-gated channels made up of combinations
of GluA1-4 subunits encoded by GRIA1-4 genes. GluA2 has an especially important role
because, following post-transcriptional editing at the Q607 site, it renders heteromultimeric
AMPARs Ca2+-impermeable, with a linear relationship between current and trans-membrane
voltage. Here, we report heterozygous de novo GRIA2 mutations in 28 unrelated patients with
intellectual disability (ID) and neurodevelopmental abnormalities including autism spectrum
disorder (ASD), Rett syndrome-like features, and seizures or developmental epileptic encephalopathy (DEE). In functional expression studies, mutations lead to a decrease in agonistevoked current mediated by mutant subunits compared to wild-type channels. When
GluA2 subunits are co-expressed with GluA1, most GRIA2 mutations cause a decreased
current amplitude and some also affect voltage rectiﬁcation. Our results show that de-novo
variants in GRIA2 can cause neurodevelopmental disorders, complementing evidence that
other genetic causes of ID, ASD and DEE also disrupt glutamatergic synaptic transmission.

Correspondence and requests for materials should be addressed to D.M.K. (email: d.kullmann@ucl.ac.uk) or to H.H. (email: h.houlden@ucl.ac.uk). #A full list
of authors and their afﬁliations appears at the end of the paper.
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A

bnormal glutamatergic synaptic transmission and plasticity has been implicated in some neurodevelopmental
disorders (NDDs) featuring intellectual disability (ID),
developmental delay (DD), and autism spectrum disorders
(ASDs)1–5, as exempliﬁed by the identiﬁcation of rare de-novo
mutations in genes encoding ionotropic glutamate receptor
(iGluR) subunit genes,6–13. iGluRs are the major mediators of fast
excitatory neurotransmission in the vertebrate brain13–17. They
include N-methyl-D-aspartate receptors (NMDARs), kainic acid
receptors (KARs), and α-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid receptors (AMPARs)14,18. AMPARs are assembled
from four subunits (GluA1-4), with GluA1/GluA2 heterotetramers being the most frequent combination in the forebrain19.
Mutations in GRIA1, GRIA3, and GRIA4 (encoding GluA1,
GluA3, and GluA4) have been established as very rare causes of
NDDs9,10,20,21. The GluA2 subunit, encoded by GRIA2, has a
major role in the regulation of AMPAR Ca2+ permeation and
voltage rectiﬁcation, in large part mediated by an arginine residue
in the ion-selectivity ﬁlter that results from post-transcriptional
editing of a codon for glutamine22,23. Hitherto, evidence for a role
of GluA2 in NDDs has been sparse. A microdeletion case report
previously suggested a possible link between GRIA2 haploinsufﬁciency and ID24, and an in-frame deletion of three amino
acids was identiﬁed in one individual recruited in the Deciphering
Developmental Disorders (DDD) study (https://www.ddduk.org/),
containing exome sequencing data from over 13,000 individuals
affected with developmental disorders3. Furthermore, abnormal
translation of the AMPAR GluA2 subunit via changes in GRIA2
expression or alternative splicing has been implicated in the
pathophysiology and the neurological phenotype of a wide array
of NDDs, including Fragile X syndrome (FXS) and Rett syndrome
(RTT)25–27. Further underlining the potential importance of
GluA2 for normal CNS development and function, Gria2−/−
mice have increased mortality, show enhanced NMDARindependent long-term potentiation, consistent with abnormal
Ca2+ permeation through GluA2-lacking AMPARs, and exhibit
impaired motor coordination and behavioral abnormalities28.
Despite the hints from the above studies, GRIA2 mutations have
hitherto not been considered an important cause of human disease, and there is no established disease association for this gene
in the Online Mendelian Inheritance in Man (OMIM) database
(MIM #138247).
We report 28 unrelated individuals, affected with neurodevelopmental abnormalities encompassing ID/DD, ASD, RTT-like
features and seizures or developmental epileptic encephalopathy
(DEE), in whom we have identiﬁed heterozygous de novo variants in GRIA2. Functional analyses reveal loss of function for the
majority of the mutations, supporting GluA2 defects as a cause of
NDDs with variable associated neurological phenotypes.
Results
Identiﬁcation of GRIA2 de-novo variants. The index case was a
4-year-old boy diagnosed with DEE (Patient 1, Supplementary
Table 1) who was found to carry a de-novo variant in GRIA2 by
trio whole exome sequencing (WES). We next screened exomes
and genomes (WGS) from the DDD Study and the SYNaPS Study
Group (http://neurogenetics.co.uk/synaptopathies-synaps) and
compared genetic datasets with collaborators and identiﬁed seven
individuals carrying GRIA2 de-novo intragenic variants (Supplementary Table 1, Patients 2–8). Through further collaborations and research networks we ascertained sixteen additional
individuals (Patients 9–25) carrying GRIA2 de-novo variants and
three individuals (Patients 26–28) with de-novo 4q32.1 microdeletions leading to GRIA2 haploinsufﬁciency (Supplementary
Fig. 1). In total, we found 20 different GRIA2 de-novo intragenic
2

variants including missense (n = 15), splice-site (n = 2), in-frame
deletion (n = 1), stop-gain (n = 1) and frameshift (n = 2) variants
(Supplementary Tables 1–2, Fig. 1a). Intragenic variants were ﬁrst
identiﬁed by WES, WGS or massively parallel targeted sequencing and conﬁrmed as de-novo by trio Sanger sequencing in all
patients (Methods, Supplementary Fig. 2). De-novo microdeletions were found by chromosomal microarray analysis (Patients
26–28) and validated using established laboratory protocols.
GRIA2 is constrained and intolerant to loss-of-function. In the
Exome Aggregation Consortium (ExAC) database (http://exac.
broadinstitute.org) GRIA2 is highly constrained for missense
variation (z-score: 4.43) and intolerant to loss-of-function (LoF,
intolerance score: 1.00)29. Among the affected probands reported
here, we found several frameshift, stop-gain and splice-site variants and 4q32.1 microdeletions predicted to lead to GRIA2
haploinsufﬁciency (Supplementary Table 2). All the identiﬁed
intragenic de novo variants were absent from Genome Aggregation Database (GnomAD, http://gnomad.broadinstitute.org) and
ExAC and displayed high conservation (Fig. 1c, Supplementary
Fig. 3) with a mean: GERP++ score 5.51 and in-silico pathogenic
predictor scores (mean: CADD_Phred 28.924). In total, in our
cohort de-novo GRIA2 variants with predicted LoF were found in
8 out 28 patients. De novo frameshift deletions in Patients 10 and
12 lead to changes in the reading frame with the generation of a
premature stop at codon 37 and 14 amino acids downstream,
respectively. In Patient 19, a single-nucleotide substitution leads
to a stop-gain variant (p.R323ter). The three de novo 4q32.1
microdeletions identiﬁed in patients 26–28 encompass
chr4:157,343,163–158,271,008 bp (GRCh37/hg19) as the smallest
overlapping deleted genomic region, and within this region
GRIA2 is the gene most intolerant to LoF (Supplementary
Tables 3–5). De novo splice-site variants in Patients 8 and 11 are
predicted to cause loss of donor splice sites at exons 1 and 11,
respectively, according to in-silico Alamut predictions (Supplementary Figs. 4–5)30. Of the other 19 patients, 18 harbored de
novo missense mutations, and one had a 9-bp deletion predicted
to lead to loss of amino acids 528–530.
Phenotypic spectrum associated with GRIA2 de novo variants.
Consistent with the role of GluA2 channels in synapse development and plasticity19, phenotypic analysis of patients carrying denovo GRIA2 variants demonstrated an NDD spectrum including
ID/DD, developmental regression, ASD, speech impairment,
RTT-like features, and seizures or DEE (Fig. 1b; Supplementary
Videos 1–5). Supplementary Table 1 summarizes the core phenotypic features of all 28 Patients, aged between 3 months and 31
years. In all cases, onset of GRIA2-related NDD occurred in
childhood. Several individuals had normal early developmental
milestones and started to exhibit variable impairment of motor
coordination, social interaction, and language abilities in infancy
(Supplementary Table 1, Supplementary Notes 2, 3, 4, and 16). In
some affected individuals, social or language regression was
reported (Patients 3 and 4). Between 2 and 6 years of age several
patients developed RTT-like features (Supplementary Table 1,
Supplementary Table 6), including stereotyped hand movements
(Supplementary Notes 2, 3, 4, and 7), screaming episodes (Supplementary Notes 2, 3, 6, and 14), gait abnormalities including
ataxia and dyspraxia (Supplementary Notes 4 and 6), abnormal
sleep rhythm (Supplementary Notes 4 and 14), and irregular
breathing patterns with hyperventilation episodes (Supplementary Note 7). Progressive microcephaly was observed in 4 out of
28 individuals (Supplementary Notes 6, 13, 17, and 21) with a
deceleration of head growth usually occurring during infancy
(Supplementary Table 1). Several patients were diagnosed with
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Fig. 1 GRIA2 intragenic de-novo variants identiﬁed in this study. a Schematic of the human GluA2 protein (NP_000817.2) indicating the positions of twelve
missense changes (dot arrows), two frameshift deletions (cross arrows), two splice-site variants (arrows) and an in-frame deletion (dot arrow). Glutamate
binding regions are displayed in red, ﬂip/ﬂop alternatively spliced region is represented in green. b Left panel: Patient 1, carrying the de-novo p.W788L
GluA2Flop variant, at 3 years, exhibitinghypotonia and an oculogyric crisis; he is wheelchair dependent. Middle left panel: Patient 2 (top) carrying the denovo p.P528_K530del in-frame deletion, at 12 years; Patient 3 (bottom) carrying the de-novo p.D611N variant, at 18 years, exhibiting hand-wringing
suggestive of RTT. Middle right panel: Patient 7, carrying the de-novo p.Q607E/p.R607G heterozygous mutation (affecting the Q/R editing site) at 10
years, exhibiting hand-wringing as part of a RTT-like presentation. Right panel: Patient 10 (top) carrying the de-novo p.F595LfsX37 variant, at 5 years;
Patient 12 (bottom) carrying the de-novo p.P286LfsX14 at 6 years. c Multiple alignment showing GluA2 protein complete conservation across species and
inter AMPAR homolog subunits (GluA1, GluA3, and GluA4) alignment. Human GRIA2 (NP_000817.2), mouse GRIA2 (NP_001077275.1), bos taurus
GRIA2 (NP_001069789.2), gallus gallus GRIA2 (NP_001001775.2), danio rerio (NP_571970.2), drosophila melanogaster (NP_476855.1), Human GRIA1
(NP_000818.2) Human GRIA3 (NP_015564.4), and Human GRIA4 (NP_000820.3)

ASD (Supplementary Notes 2, 3, 9, 10, 11, 12, 15, 19, 22, 23, and
26), and some presented repetitive behavior patterns and
impaired social interaction (Supplementary Notes 8, 27, and 28).
Language impairment was present in all patients, with the
majority attaining no meaningful speech (Supplementary
Table 1). Twelve patients suffered from seizures (Supplementary
Notes 4 and 5) or DEE (Supplementary Notes 1, 7, 13, 16, 17, 18,
20, 21, 24, and 25) usually starting within the ﬁrst 6 months of
life, including infantile spasms, tonic-clonic, myoclonic and focal
seizures (Supplementary Table 7). EEG features included polyspikes, slow spike and wave, and bilateral temporal nonsynchronized epileptic activity. The clinical outcome was also
variable (Supplementary Table 1, Supplementary Notes 1, 7, 13,
16, 17, 18, 20, 21, and 24). MRI scans in 7 DEE patients showed
progressive brain (mainly cerebellar) atrophy and white matter
abnormalities in some (Fig. 2; Supplementary Table 1).
AMPAR Molecular dynamic stimulations. To compare the
structural mobility of GluA2 and its mutants we built a model of
each protein ectodomain including a ligand-binding domain
(LBD) and an amino-terminal domain (ATD; Methods) by
modeling mutations on the wild type and followed their behavior
along time by means of atomistic molecular dynamics simulations
in water solvent. Proteins with mutations in the pore region
where omitted as either the mutations were close to or included in
the transmembrane domains (TMDs) which were not modeled.
We aimed to ascertain the effect of the mutations on the glutamate (GLU) binding-pocket. Interestingly, in the studied mutated

proteins this group of atoms appear to have a higher level of
rigidity compared to the wild-type protein (Figs. 3 and 4).
Although the wild-type crystal structure is symmetric, after 10 ns
the conformations of pockets associated with chains C and D,
which are coupled in the binding site, diverge with respect to
those associated with A and B which do not change conformation. In the observed timeframe molecules underwent concerted
macroscopic movements and this is reﬂected by minor variations
in their backbone root mean squared deviation (RMSD, Supplementary Fig. 9) and radius of gyration (Supplementary Fig. 10).
The RMSD, which is a measure of the average atoms displacement from the starting conﬁguration, clearly indicates that amino
acids in the GLU binding site are independently mobile at a
timescale consistent with our simulations with two pockets
reaching values larger than 0.27 nm. However, the same is not
true for most mutants: p.D302G, p.F644L, p.P528T, and p.V647L
whose RMSD do not exceed 0.22 nm. The remaining mutants
studied showed an intermediate behavior.
Functional analyses of the identiﬁed GRIA2 variants. To assess
the functional consequences of GRIA2 missense mutations, we
synthesized cDNA encoding the human GluA2 wild-type and
mutant channels and transfected HEK293T cells together with the
auxiliary stargazin protein (Methods). Except for one mutation
(see below), amino acid position 607 was made to encode an
arginine residue in GluA2 to mimic post-transcriptional editing
of a genomic glutamine-encoding codon. Coding variants in the
N-terminal domain, linkers (including the three amino acid
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Fig. 2 Brain imaging in 4 individuals with GRIA2-related DEE and brain and cerebellar atrophy. a Sagittal T1 weighted (left panel), Axial T1 weighted (middle
panel), and coronal T2 weighted (right panel) images from Patient 1 (carrying the de-novo p.W788L mutation) scanned at the age of 3 years. There is
reduction in the cerebral white matter (red and white arrows), brain volume and marked cerebellar atrophy with vermian deﬁciency (white arrows).
b Sagittal T1 weighted (left panel) images from Patient 13 (carrying the de-novo p.T646N mutation) at the age of 2 months, and axial T1 weighted (middle
panel) and coronal T2 weighted images (right panel) from the same Patient at the age of 11 months demonstrate white matter signal abnormality (white
and red arrows) with generalized reduction in the cerebral white matter volume and cerebellar atrophy with vermian deﬁciency (white arrows). c Sagittal T1
weighted (left panel), Axial T2 weighted (middle panel) and coronal T2 weighted (right panel) images from Patient 17 (carrying the de-novo p. A639S
mutation) at the age of 6 days; there is an underdeveloped/hypoplastic cerebellum (white arrows) and delayed maturation of myelin. d Sagittal T1
weighted (left panel), axial T1 weighted (middle panel) and coronal T2 weighted (right poanel) images from Patient 18 (carrying the de-novo p.V647L
mutation) scanned at the age of 18 months; there is a global cerebral atrophy and white matter changes which suggest hypomyelination (white and red
arrows). Although the volume of the cerebellar hemispheres is preserved, atrophy of the inferior cerebellar vermis and wide cerebellar sulci are seen

deletion) and pore were selected for functional analysis. Inward
currents evoked by the non-desensitizing agonist kainic acid (KA,
1 mM) on HEK cells expressing homomeric GluA2 were signiﬁcantly decreased for 7 out of the 11 variants tested, including
those associated with NDD or NDD and DEE (Fig. 5a). Three
variants (p.P528T, p.D611N, and p.V647L) exhibited apparently
normal current amplitudes. In contrast, the p.Q607E variant
exhibited KA-evoked currents that were larger than the wild-type
control. This mutation affects the Q607 codon that is normally
edited to an arginine residue. The increase in current amplitude is
consistent with removal of a positively charged residue from the
ion conduction pathway.
GluA2 homomers are not thought to occur naturally. A
common stoichiometry in the forebrain is channels composed of
two GluA1 and two GluA2 subunits. Presence of the GluA2,
edited at the Q607 site, in the heteromeric channel reduces the
single channel conductance, confers Ca2+-impermeability, and
results in a linear current-voltage relationship22,23. In contrast,
homomeric GluA1 channels exhibit a larger rectifying
4

conductance and are Ca2+-permeable. We therefore repeated
the functional studies co-expressing wild type or mutant GluA2
together with GluA1 and stargazin. Wild-type GluA2 coexpressed with GluA1 yielded approximately two-fold larger
KA-evoked currents than GluA1 alone (Fig. 5b). Five of the
mutants signiﬁcantly decreased the KA-evoked current amplitude
relative to wild-type GluA2. Interestingly, two of these variants (p.
D302G and p.G609R) reduced the current below the level
obtained with GluA1 alone, suggesting a dominant negative effect
(Fig. 5b). Of the remaining variants, all but one (p.P528T)
exhibited an apparent decrease relative to wild type, although
falling short of signiﬁcance.
We complemented the KA-evoked current amplitude measurements with assessment of rectiﬁcation by ramping the holding
voltage between −104 and +76 mV. We conﬁrmed that GluA1
expressed alone yielded a doubly rectifying current-voltage
relationship. It was linear when wild-type GluA2 was coexpressed (Fig. 6). Seven of the mutants signiﬁcantly increased
the degree of rectiﬁcation compared to wild-type GluA2.
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Fig. 3 Molecular modeling and predicted consequences of 6 GRIA2 de-novo missense variants Left panel: Six modeled GRIA2 de-novo missense variants
(highlighted in purple within red rectangle) affecting the amino-terminal domain (ATD) and ligand-binding domain (LBD) of GluA2; Middle panel: particular
of the wild-type GlUA2 residue; Right panel: particular of the mutated GluA2 residue. a For variant p.G47E, the presence of the glutamic acid residue (right
panel) in place of the glycine residue (middle panel) is predicted to cause the formation of two hydrogen bonds with a neighboring arginine residue;
hydrogen bond distances are shown for the mutant structure. b The presence of a Threonine residue in position 528 (right panel) is predicted to cause a
slight change in the backbone conformation of the neighboring residues that, in turn, allows hydrogen bonding formation between the two chains forming
the LBD domain. c Mutation p.F644L causes the loss of hydrophobic interactions between residue 644 and the side chain of Lys532. d For mutation p.
T646N, the presence of a more hydrophilic Asparagine residue increases the distance between the distal chains by about 3 Å, at the interface of LBD and
TMD (right panel). e For mutation p.V647L, increased hydrophobicity of Leucine (right panel) compared to Valine (middle panel) increases the separation
of helices at the interface between LBD and TMD by about 2 Å. f For variant p.G792V, the presence of a more hydrophobic Valine residue in close
proximity to the binding site is predicted to cause a sliding movement with respect to the neighboring chain, disrupting the interchain salt bridge between
Glu655 and Lys797; hydrogen bond distance is shown in the wild-type GluA2 (middle panel)
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Fig. 4 GluA2 Molecular dynamic stimulations predict reduced mobility at the agonist binding site. Root Mean Square Deviation (RMSD) of the GluA2
Glutamate binding pocket (GLU) amino acids along the simulated time for the wild-type protein (top left) and GRIA2 mutants (a–i). In all panels the color
code is: chain A (blue/cyan), chain B (black/yellow), chain C (red/orange), and chain D (light/dark green). Thicker lines indicate running averages over
100 samples

Although consistent with partial or complete loss of GluA2
incorporation in surface-expressed channels, this does not explain
why some mutations that affected rectiﬁcation, including p.
Q607E, did not signiﬁcantly reduce the KA-evoked current
amplitude. Indeed, when voltage ramps were applied to cells
expressing p.Q607E without GluA1, the current-voltage relationship was strongly rectifying (Fig. 7), as expected from loss of a
polyamine-repelling positively charged residue. Overall, all but
one variant (p.P528T) affected either KA-evoked current
amplitude or rectiﬁcation or both when co-expressed with
GluA1, although in some cases the effects fell short of signiﬁcance
when unpaired t-tests included Holm-Bonferroni correction for
multiple comparisons (Fig. 8, Supplementary Table 8).
To determine whether mutations affect channel synthesis or
trafﬁcking, we used a biotinylation assay to probe surface
expression of selected mutants. When co-expressed with GluA1,
p.A639S exhibited a decrease in total expression of GluA2 (Fig. 9,
Supplementary Fig. 6). As a fraction of total GluA2, protein at the
cell surface was decreased for p.A639S, but also for p.Q607E,
consistent with evidence that the arginine normally present at
codon 607 affects trafﬁcking31 (Fig. 9).
We modiﬁed the GluA2 sequence to examine the effect of two
further codon changes. p.I375V, which is found in 103 subjects
out of 60706 individuals from the ExAC database and is therefore
likely to be a low-frequency variant of uncertain signiﬁcance, this
6

increased the current carried by homomeric channels, but not
when co-expressed with GluA1 (Supplementary Fig. 7). We also
introduced another codon change, p.A643T, that corresponds to
the Lurcher mutation in the related non-functional receptor
GluD2, because it is near a cluster of 4 mutations identiﬁed in the
cohort (p.A639S, p.F644L, p.T646N, and p.V647L). The Lurcher
mutation disrupts murine cerebellar development and function
by creating a leaky receptor that ﬂuxes cations in the absence of
ligand. When introduced in GluA2, p.A643T was non-functional,
and the holding current was no different from WT-expressing
cells (or indeed, cells expressing any of the other variants tested,
Supplementary Fig. 7). We conclude that loss of function is
caused by multiple molecular mechanisms involving both altered
channel surface expression and altered channel function, and that
the mechanisms do not involve a Lurcher-like leak conductance
(Supplementary Fig. 8).
Discussion
The genetic and functional expression data presented here identify de-novo mutations and microdeletions involving GRIA2 as a
cause of NDDs and DEE and underline the importance of the
GluA2 subunit in the regulation of Ca2+ permeation and voltage
rectiﬁcation of AMPARs and therefore in human synaptic plasticity and brain development and function22,23,28.

NATURE COMMUNICATIONS | (2019)10:3094 | https://doi.org/10.1038/s41467-019-10910-w | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10910-w

a

KA-evoked current: GluA2 homomers
WT

D302G

Q607E

A639S

V647L

1 nA

***

4
3
2
1
0

***

*

*

***

***

***

***

G

W

T

47
E
D
30
2G
P5
Δ5 28T
28
–5
30
Q
60
7
G E
60
9R
D
61
1N
A6
39
S
F6
44
T6 L
46
N
V6
47
L

Amplitude (nA)

2s

b

KA-evoked current: co-expressed with GluA1
—

WT

##

Q607E

#
***

**

###
***

A639S

**

V647L

***

*

4
2

61
1N
A6
39
S
F6
44
T6 L
46
N
V6
47
L

D

7E
60
9R

60

G

Q

T

30
–5

Δ5

28

2G

28

P5

D

30

E
47
G

W

T

0
—

Amplitude (nA)

D302G
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The structure of each GluA2 subunit includes (i) a large ATD
(ii) a LBD formed by the proximal part of the N terminus (S1
lobe) and the large loop between transmembrane segments M3
and M4 (S2 lobe) (Fig. 1), (iii) a TMD formed by hydrophobic
membrane-spanning helices M1, M3 and M4 and the M2 helix
and re-entrant loop, and (iv) a carboxy-terminal (CTD) intracellular region involved in synaptic localization and receptor
regulation30,32. The intracellular M2 loop together with the M3
helix form the ion-conducting pore33. Receptor subunits ﬁrst
form dimers, then tetramers, and structural studies reveal 2-fold
symmetry of the extracellular domains which transitions to 4-fold
symmetry in the transmembrane domains34. Three ﬂexible
stretches of amino acids link the ligand-binding domain to the
transmembrane helices and allow energy transfer from the agonist binding site to the channel gate at the top of M3.
GluA2 subunits are post-transcriptionally edited at the Q/R site
at position 607, where M2 protrudes into the pore, rendering the
channel non-rectifying and calcium-impermeable. In adults,
nearly 100% of GluA2 subunits are in the edited R form. The p.
Q607E mutation identiﬁed in the present study is caused by a
cytosine to guanidine base change immediately 5′ to the adenosine that is edited to inosine by ADAR2. The normal editing
results in a glutamine (CAG) to arginine (CIG) change, because
the inosine base is read as a guanosine by the ribosome. ADAR2
recognition assays predict that the mutant codon (GAG) is edited
~90% less than the normal CAG35, so we did not investigate the
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effect of a glycine (GGG) residue at position 607. When GluA2
was expressed in HEK cells, we observed increased current for
Q607E homomers which also exhibited inward rectiﬁcation.
During experiments, we also noticed fewer surviving HEK cells,
suggesting a possible toxic effect of this mutation. In contrast,
another disease-associated mutation two codons 3′ from codon
607, p.G609R, almost eliminated current in both homomeric and
co-expression experiments. Site-directed mutagenesis at or near
the Q/R site 607 was previously shown to cause misassembled
homomeric GluA2 channels which are retained in the ER32. Our
data suggest that GluA2 subunits with the G609R mutation are
trafﬁcked to the surface but are non-functional and cause coexpressed subunits to also be non-functional. The p.D611N variant had a milder effect, with a trend towards decreased function
when co-expressed with GluA1.
Importantly, de novo missense variants affecting the M3
channel gate or the M3-S2 linkers have been previously identiﬁed
in several iGluR subunit genes (e.g., GRIA1, GRIA3, and GRIA4);
phenotypes of these patients include ID, autism and epilepsy7–10.
We identiﬁed four mutations associated with neurodevelopmental phenotypes in on near the SYTANLAAF motif, a highly
conserved nine-amino acid region at the top of the M3 transmembrane helix, which forms the channel gate36. Extensive prior
work demonstrates the sensitivity of this motif to mutation across
the iGluR superfamily. For example, a mutation associated with
NDD affecting the eighth residue in GluA1 (p.A636T; SYTANLAAF) results in leaky channels9, and the equivalent mutation (p.
A654T) in the GRID2 gene (encoding the GluD2 receptor) was
associated with human movement disorder37 as well as the
Lurcher mouse ataxic phenotype38. We tested the analogous
GluA2 p.A643T as a positive control in our electrophysiology
experiments and observed loss of KA-evoked current but no
change in holding current that would suggest a leak. The p.A653T
mutation in GluA3, affecting the seventh residue (SYTANLAAF),
causes NDD and altered sleep and eliminates KA-evoked currents20. Structural data in GluA2 homomers places this residue in
close proximity to A639 (SYTANLAAF) of the adjacent subunit
and suggests that A639 may act as a ‘hinge’ in the
M3 structure39,40. In our study, p.A639S caused loss of KAevoked current in GluA2 homomers and a decrease in current
when GluA1was co-expressed, showing that this position is
highly sensitive to even a conservative amino acid change. The
p.F644L variant is the top of the SYTANLAAF motif, and p.
T646N and p.V647L map two and three amino acids downstream
of the SYTANLAAF motif, respectively. For p.V647L, an inherited mutation at the equivalent site in GRIA1 (p.V640L) caused
ASD9. For p.T646N, reduced current in GluA1-GluA2 coexpression and partial reduction in RI would be consistent with
reduced surface expression combined with impaired channel
gating (although a decrease in surface expression was observed it
did not reach signiﬁcance). Molecular dynamic simulations
indicated a loss of symmetry between subunit pairs in the presence of p.T646N, with Chain B alone becoming more mobile, in
contrast with the WT channel where chains moved in pairs
(Fig. 4). This suggests that p.T646N compromises tertiary structure stability. In contrast, p.F644L appeared to be robustly
expressed but caused reduction in currents to below the level of
GluA1 when co-expressed, demonstrating a gating deﬁciency
which impacts co-assembled WT subunits.
In summary, we noted that effects on currents greatly varied
among mutants, with striking differences even when comparing
nearby residues. Three mutations (p.D302G, p.G609R, p.F644L)
eliminated the GluA1 current when co-expressed, suggesting that
they lock other subunits into non-functional channels. They are
all located in different domains. Perhaps surprisingly, these
mutations are not clearly associated with a more severe
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phenotype. For another three mutations (p.G47E, p.Q607E, and
p.A639S), GluA2 surface protein was signiﬁcantly reduced in the
co-expression western blots, showing that defects in heteromerization and/or surface trafﬁcking contribute to some phenotypes. This mechanism also shows no correlation with structural

ARTICLE

location, again highlighting the diversity among the tested
mutants. In general, we are unable to predict clinical severity on
the basis of receptor physiology. However, in the case of p.Q607E,
we speculate that gain-of-function in the homomeric channel
could explain the patient’s seizures. The most severe clinical cases
were associated with p.A639S, which caused epileptic encephalopathy and death in infancy. This mutation caused a signiﬁcant
reduction in total GluA2 protein, but our analysis was hampered
by a lack of transfected cells, suggesting that this mutation should
be investigated for cellular toxicity.
Further clues to the function of GluA2 come from genetically
engineered mice. “Q/R” editing-deﬁcient knock-in mice die of seizures at 3 weeks41, whilst Gria2−/− mice have increased mortality,
impaired motor coordination and behavioral abnormalities28.
Gria2−/− mice also exhibit enhanced long-term potentiation in
hippocampal principal neurons that is resistant to blockade of
NMDA receptors, consistent with Ca2+ entry via AMPARs triggering an increase in synaptic strength. A similar NMDARindependent form of LTP normally occurs in a subset of interneurons with rectifying AMPARs, which are deﬁcient in GluA242.
Although heterozygous Gria2+/− mice are developmentally normal,
they also exhibit NMDAR-independent long-term potentiation in
principal neurons, albeit less than homozygous mice43.
The difference between the severe neurodevelopmental phenotypes reported in the present study and the heterozygous mice
suggests that the human brain is more sensitive to AMPAR
dysfunction. For several mutations associated with either NDD or
DEE we observed increased rectiﬁcation of AMPARs when
GluA1 and mutant GluA2 were co-expressed, consistent with
failure to incorporate mutant GluA2 in heteromeric channels.
Although no clear genotype-phenotype correlations emerge for
the majority of patients, we did observe a striking correspondence
between speciﬁc recurrent mutations and the individual phenotypes. Speciﬁcally, the p.Val647Leu variant was associated with
DEE in 3 cases who showed overlapping electro-clinical features
(Supplementary Table 6). Moreover, two individuals (Patient 17,
20) who died with sudden unexplained death in epilepsy
(SUDEP) carried the same p.Ala639Ser mutation affecting a
conserved Alanine residue proximal to the SYTANLAAF domain.
The phenotypic differences in the remaining individuals may
arise from different effects of distinct mutations that the in vitro
experiments fail to capture. A potential limitation of the present
study is that kainate was used as a non-desensitizing agonist.
Rapid application of glutamate to outside-out membrane patches
may uncover alterations in kinetics that were not captured with
kainate application to HEK cells recorded in whole-cell mode.
Another possible area for study is the interaction with stargazing
and other auxiliary proteins. However, in pilot experiments
without stargazin co-expression, no kainate-evoked currents were
observed, limiting our ability to quantify this interaction. Further
possible contributions to the phenotypes are the effects of modifying genes and stochastic processes during development44. The
broad range of phenotypes associated in GRIA2 mutations
identiﬁed here is reminiscent of the variable neurological phenotypes reported in association with mutations in other genes
encoding homologous AMPAR/NMDAR subunits 7–11,18,20,21.
These include the AMPAR subunit genes GRIA1, GRIA3, and
GRIA4, causing an NDD spectrum including ID, loss of speech,
epilepsy, gait abnormalities, and abnormal sleep patterns9,10,20,21.
It is highly likely that dysregulation of a number of transcriptional and post-transcriptional modulations is implicated in
the GRIA2 neurodevelopmental disorders. Further studies will
determine whether the expression proﬁles of other genes or
proteins contribute to the phenotype associated to GRIA2 or
other AMPAR subunit gene mutations. In patients with GRIA2related disorders, NDD is often associated with a number of
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additional clinical features, including neurological and psychiatric
comorbidity and other systemic signs, implying that affected
individuals should have regular neurological and neuropsychiatric assessments. In a proportion of cases, variants were identiﬁed
from independent groups of individuals affected with molecularly
undeﬁned DEE or RTT-like syndrome (Supplementary notes,
Supplementary Tables 5–6). However, WES in our cohort did not
identify any pathogenic variants in known NDD- or DEEassociated genes, including MeCP2 and CDKL5 which underlie
RTT and RTT-like (or DEE) phenotypes, respectively. For
patients 26–28, other genes within the 4q32.1 deletion may also
contribute to aspects of their clinical phenotype.
Genes associated with DEEs and NDDs that do not encode
glutamate receptors may also have an impact on the regulation of
excitatory synaptic strength through a variety of mechanisms
including GRIA2 translation and alternative ﬂip/ﬂop splicing26,27
and abnormal editing at the Q/R site has been also implicated in
neurological disorders45–47. Taken together, these studies implicate GluA2 dysfunction as a point of convergence for multiple
genetic disorders underlying NDD and DEE. Further research is
needed to establish the full range of neurological disorders
relating to abnormal GluA2 expression and conductance, and to
establish whether drugs targeting AMPARs, such as AMPAkines,
would ameliorate clinical outcomes. At present, given the evidence for both a decrease in AMPAR function and an increase in
Ca2+ permeability, we urge caution in extrapolating whether
AMPAR inhibitors or desensitization blockers are candidates.
Methods
Patients recruitment. For each affected individual, clinical data as well as brain
imaging and EEG were reviewed by the clinicians (geneticists, neurologists,
pediatricians) from the participating centers. Genomic DNA was extracted from
the whole blood or saliva of the affected individuals and their parents. Informed
consent for DNA analysis was obtained from study participants in line with local
institutional review board requirements at the time of collection. The study was
approved by the ethics committee of University College London (07/Q0512/26)
and additional local ethics committees of the participating centers. We complied
with all relevant ethical regulations for human patients and obtained informed
consents from all the families involved in this study. Families from research participants provided informed consent for publication of the images in Fig. 1b and for
publication of videos in the Supplementary Information. Parents of the affected
individuals (and when available unaffected siblings) were recruited for segregation
analysis, which was carried out using Sanger sequencing. Individuals diagnosed
with NDD (including ID, DD, ASD, RTT-like and DEE) were recruited in the
different centers participating to the study. Based on the International League
against epilepsy (ILAE) classiﬁcation, a DEE was deﬁned in the patients as
refractory seizures and cognitive slowing or regression associated with frequent,
ongoing epileptiform activity48. Based on the RTT diagnostic criteria49,50, the
affected individuals from this cohort have at least 1/4 main RTT criteria and
≥4 supportive criteria51,52. ID was deﬁned based on the presence of signiﬁcant
deﬁcits in conceptual, social and/or practical skills associated with signiﬁcant
deﬁcits in adaptive behavior53. Detailed epilepsy and medical histories were
obtained together with the results of investigations including EEG and MRI studies.
The 28 individuals carrying de-novo GRIA2 intragenic variants and 4q32.1
microdeletions (Supplementary Figs. 1 and 2, Supplementary Tables 1–4) were
recruited from different research groups and consortia in the UK and internationally. Individuals 1, 4, and 17 were studied as part of the SYNAPS Study
Group initiative (http://neurogenetics.co.uk/synaptopathies-synaps/). Individuals 3
was initially referred for trio WES to diagnostic laboratories (GeneDX: https://
www.genedx.com) from their clinicians from different centers and and followed-up
as also part of the SYNAPS Study Group cohort of patients. Also, individuals 6, 7,
8, 21, 22, 24, and 25 were sequenced by trio WES at GeneDX. Individual 2 was
initially recruited as part of the DDD Study (DDD4K.03245) and also followed-up
in the SYNAPS Study Group. Individuals 10, 11, 12, and 15 were recruited as part
of the Autism Clinical and Genetic Resources in China (ACGC)54 study in China,
which consist of more than 4000 individuals affected with ASDs. Patient 19 was
recruited in “The Autism Simplex Collection” cohort consisting in 1700 WES trios.
Patient 14 was identiﬁed by analyzing the negative exome sequencing data from a
published cohort of patients with RTT-like features or DEE51. Patient 9 was
recruited as part of a project on the genetics of developmental disorders at University Hospital Pitié- Salpêtrière in Paris. Individuals 13, 16, and 18 were recruited
within single Institution Epilepsy research centers University Hospital d’ enfants
Armand Trousseau, University Hospital of Angers, University Hospital of Melbourne) as part of genetic analysis for undiagnosed infantile-onset epileptic
10

encephalopathies. Individual 5 was recruited at the Leiden University Medical
Center as part of a research project on ID and then was submitted to DECIPHER
(DECIPHER ID: 322236). Patient 20 was recruited at University Hospital of Sao
Paulo. Patient 21 was identiﬁed at University of Amsterdam. Patient 22 was
identiﬁed and genetically investigated at the Center for Autism and Related Disorders in the Kennedy Krieger Institute. Patient 23 was recruited at the Child and
Adolescent Psychiatry Unit of the Universidad Complutense in Madrid, Spain.
Patient 24 was recruited at Mayo Clinic. Patient 25 was recruited as part of the Care
for Rare Program at Ottawa University Children’s Hospital in Canada. Individuals
26, 27, and 28 were studied by micro-array analysis as part of single Institutions
projects on copy number variants in neurodevelopmental phenotypes and also
submitted to DECIPHER (DECIPHER IDs: 328135, 269176, and 296516, respectively). Initial diagnostic work-up (including genetic and metabolic investigations)
was normal in all cases. All families gave written informed consent for inclusion in
the study and consent for the publication of photographs was obtained for individuals 1, 2, 3, 7, 10, and 12.

Genetic analyses. All research centers involved in this study followed a trio-based
WES or targeted sequencing approach to identify the de novo GRIA2 variants as
the cause of the neurodevelopmental phenotypes of the patients. The DDD Study
analyzed more than 13,000 children with severe developmental disorders and their
parents3, GeneDx laboratory analyzed over than 11,000 individuals affected with
NDDs with at least 9000 of them being sequenced with both parents and following
the method described above, the SYNAPS Study Group analyzed approximately
260 trios of children with NDDs and EE, the Leiden University Medical Center
tested over than 500 ID trios55. Following their respective analysis pipelines, participating centers generated a list of candidate variants ﬁltered against public
database variants and according to modes of inheritance. All variants reported in
the present study were determined independently by participating centers. Connecting the different contributing centers was facilitated by the web-based tools
GeneMatcher31 and DECIPHER56. Variants of interest in GRIA2 gene were mostly
identiﬁed by WES of trios (Individuals 1, 3, 4, 5, 6, 7, 8, 9, 13, 14, 16, 17, and 18)
and targeted sequencing with Molecular Inversion Probes (MIPs, individuals 10,
11, 12, 15, and 19), or Microarray analysis (Individuals 26, 27, and 28). In individuals 3, 6, 7, and 8, trio-based WES was performed at GeneDX using the Clinical
Research Exome kit (Agilent Technologies, Santa Clara, CA). Massively parallel
(NextGen) sequencing was done on an Illumina system with 100 bp or greater
paired-end reads. Reads were aligned to human genome build GRCh37/UCSC
hg19, and analyzed for sequence variants using a custom-developed analysis tool57.
Individuals 10, 11, 12, 15, and 19 were studied through targeted sequencing of ASD
candidate genes including GRIA2 from a cohort of 3910 ASD individuals recruited
as part of the ACGC study using a single-molecule molecular inversion probes
method54. Reads were aligned against hg19 with BWA-MEM (v0.7.13) after
removing incorrect read pairs and low-quality reads and single-nucleotide variants
and indels were called with Free Bayes (v0.9.14). For Individuals 1 and 17 Nextera
Rapid Capture Enrichment kit (Illumina) was used according to the manufacturer
instructions. Libraries were sequenced in an Illumina HiSeq3000 using a 100-bp
paired-end reads protocol. Sequence alignment to the human reference genome
(UCSC hg19), and variants call and annotation were performed using in-house
pipelines39,41. Libraries were prepared from parent and patient DNA, and exomes
were captured and sequenced on Illumina sequencers. Raw data were processed
and ﬁltered with established pipelines at the academic or diagnostic
laboratories58–62. Variant (single nucleotide and indel) calling and ﬁltering was
performed using the Genome Analysis Tool Kit (GATK; see URLs). Variants that
did not adhere to the following criteria were excluded from further analysis: allele
balance of >0.70, QUAL of <20, QD of <5, and coverage of <20×. Variants were
annotated and the Exome variant server ESP6500 (see URLs) was used to assess
variant frequency in the control population. In the index case (Individual 1) trio
WES, the average sequencing depth of the on-target regions was 76.8 reads per
nucleotide, with 96.8% of the regions covered at least 20×. In our analysis, we
excluded non-exonic variants and exonic synonymous variants and prioritized rare
variants (with a frequency <1% in ExAC and 1000 Genomes project). Traditional
Sanger sequencing was used to validate the variants and to assess their segregation
within the families (detailed conditions of the primers used, and sequencing
methods are available upon request). In regard to variants ﬁltering and interpretation, autosomal recessive and dominant de-novo mutations were prioritized
in our analysis at the different centers. Variants were annotated using the Variant
Effect Predictor (Ensembl release 75) based on Sequence Ontology nomenclature:
missense variant, initiator codon variant, splice donor or acceptor variant, frameshift variant, stop lost, stop gained, in-frame insertion or deletion. We prioritized annotations using the transcript associated with the most severe consequence
for each variant and, in case of similar consequences, we prioritized the ﬂip
transcript (NM000826.3) being the one with largest base pairs length. To exclude
likely benign amino acid changes, non-synonymous variants were further considered if predicted damaging by at least 3 out of 5 in-silico methods among
PolyPhen-2, SIFT, Mutation Taster, Condel and CADD (see URLs). Variants that
were not present in both the mother and the father of the probands were considered de-novo. In recessive ﬁltering, we included homozygous, hemizygous or
compound heterozygous variants. Variants present in >1% of our internal exome
dataset at the UCL Institute of Neurology (containing ~5000 exomes from
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individuals affected with a range of neurological disorders) were excluded. Exome
data were analyzed for variants in genes linked before to RTT or RTT-like syndrome, epilepsy and NDDs, and for variants in other genes not linked to diseases.
Genes involved in EE and RTT-like presentations were retrieved from the literature58. Based on values from the ExAC database (containing 60,706 individuals),
variants in genes with high probability of being LoF intolerant (i.e., ExAC pLI >0.9)
and highly constrained for missense variations (Z-score >2) were prioritized. In the
case of candidate genes, variants in genes whose homologs are known to be
implicated in neurological and neurodevelopmental disorders were prioritized in
the analysis. Patient was analyzed in the discovery phase of this study and found to
carry a single de-novo exonic variant (with a MAF <0.001) in GRIA2
(NM001083619.1: c.2363G>T; p.Trp788Leu). This was conﬁrmed by Sanger in the
trio. Similarly to the index case (Patient 1), also in other research and diagnostic
laboratories the identiﬁed variants in GRIA2 were prioritized and emerged as the
most likely explanation for the individuals disease pathogenesis, as supported by (i)
high conservation of the affected residue across species, as well as in-silico analysis
and high pathogenic scores (Supplementary Table 1); (ii) biological importance of
the residues affected by the mutations (the identiﬁed variants mostly affect conserved sites within the transmembrane domain known to be important in GluA2
and AMPAR function); (iii) crucial function of the gene and its encoded protein in
synaptic plasticity and brain development and function; (iv) publications linking
this gene homologs (GRIA1, GRIA3, GRIA4) to similar NDD phenotypes; (v) denovo occurrence of the GRIA2 variants which was demonstrated in all the
laboratories by trio-based traditional Sanger sequencing. The comparison of phenotypes across the different GRIA2 mutated individuals identiﬁed within the different centers involved the study conﬁrmed the implication of GRIA2 de-novo
variants in the observed spectrum of neurological abnormalities.

Functional characterization of the identiﬁed GRIA2 variants. Human GluA2
(ﬂip, Q/R edited) plasmids were produced under contract by Genscript, USA.
cDNA was synthesized and cloned into pcDNA3.1+ using HindIII and XhoI, prior
to mutagenesis. pIRES2-GFP-Stargazin was a gift from Stuart Cull-Candy and
Mark Farrant, University College London. HEK cells were cultured in DMEM with
10% FBS and passaged 2 times per week. Cell line veriﬁcation was not carried out,
however all experiments used the same frozen stocks and mutant experiments were
interleaved with controls. Twenty-four hours prior to transfection, HEK cells were
seeded in 6-well plates at a cell density of 300,000 cells/well in 2 mL media. For
western blots the wells were pre-coated with poly-D-lysine. Cells were transfected
using TurboFect (ThermoFisher, UK) according to the manufacturer’s protocol.
For experiments testing homomeric channels, 1.5 µg GluA2 (WT or mutant)
plasmid was combined with 1 µg stargazin-GFP plasmid. Negative controls for
western blots excluded GluA2. For experiments testing co-expressed GluA1 and
GluA2 (WT or mutant), both plasmids and stargazin were co-transfected at 0.7 µg
each. GluA1 without GluA2 acted as the negative control. Transfection proceeded
for 4–6 h, and then cells were washed (for Western blots) or re-plated onto poly-Dlysine coated 13 mm round coverslips (for electrophysiology).
Cells were perfused with external solution composed of (mM): NaCl 140, KCl
2.4, CaCl2 2, MgCl2 1, HEPES 10, Glucose 10; pH 7.4 (NaOH). Internal solution
was composed of (mM): CsCl 145, CaCl2 2, MgCl2 2, EGTA 10, HEPES 10, Glucose
17.5; pH 7.4 (CsOH). Patch pipettes were typically of 4.5MΩ resistance after
polishing. Cells were whole-cell voltage clamped at −74 mV (adjusted for a liquid
junction potential of 4 mV). Series resistance did not exceed 25 MΩ and
compensation was not applied. Data were acquired with a Multiclamp 700B
(Molecular Devices, USA), logged at 1 kHz using a BNC-2090A (National
Instruments, USA) and WinEDR version 3.8.0 (University of Strathclyde, UK).
Cells on coverslips were secured in a custom-made bath and visualized by GFP
ﬂuorescence on an IX73 inverted microscope (Olympus). Kainic acid (Hello Bio,
UK) was diluted freshly on the day of recording at 1 mM. Control and drug
solutions were applied to a patch-clamped cell in parallel streams through a glass
theta tube (TGC150–10, Harvard Apparatus), pulled with openings ~300 µm wide.
We used a hand-operated piezo manipulator (Scientiﬁca) to switch solutions,
giving exchange times of ~100 ms. Where GluA1 and GluA2 were co-expressed,
incorporation of both subunits was probed with voltage ramps from −104 to +
76 mV, over 1.8 s. Peak current amplitude was measured using WinEDR. Ramp
currents during kainate application were analyzed using a custom Python script.
For the biotinylation assay, the cells were washed with buffer PBS containing
0.1 mM CaCl2 and 1 mM MgCl2 (PBS-CM) and incubated with 600 μl of the same
buffer containing 0.5 g/ml of sulfo-NHS-Biotin (Thermo Fisher) for 30 min on ice.
The cells were then washed with 100 mM glycine in PBS-CM and incubated in the
same buffer 20 min on ice. After that, cells were washed twice with PBS and lysate
with 300 μl of lysis buffer composed of: 100 mM NaCl, 5 mM EDTA, 1% (v/v)
Triton X-100, protease inhibitor cocktail (Sigma) and 50 mM HEPES, pH 7.4 (pH
7.4). Remained cells were scraped and then sonicated for 5 min in a 0.5 ml
microcentrifuge tube and vortexed 15 min at RT. Then, the lysate was centrifuged
10 min at 20,000 × g 4 °C. Aliquots of 15 μl of supernatant were stored as “input
controls” and the remaining supernatant was added to 40 μl of Neutravidin-agarose
beads (Thermo Fisher) previously washed twice with lysis buffer, and incubated on
a rotor wheel for 1 h at RT. Samples were then eluted with 4x LDS sample buffer
for 20 min at 76 °C. Input (lysate, 1.25% of total) and eluates (33% of total) were
subjected to SDS–PAGE (Bis–Tris 4–12% gradient gels, Invitrogen) in MES buffer
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(Invitrogen), and transferred to PVDF membranes. The membranes were
immunoblotted whit primary antibodies anti-GluA1, anti-GluA2 (Alomone Labs,
#cat: AGC-004 and AGC-005, concentration 1:500) and anti-GAPDH (Abcam,
#cat: ab9483, concentration 1:5000) over night and secondary HRP antibody for
30 min. Quantiﬁcation was performed using Bio-Rad Image Lab. Reproducibility of
results was conﬁrmed by performing three independent experiments.
Statistics. Statistics were performed in Python version 3.6.1 (Anaconda version
4.4.0) with scipy version 0.19.0 and statsmodels version 0.8.0. Data for mutant
channels were compared with WT using independent t-tests in scipy.stats, without
assuming equal variances (Welch’s correction). P-values were then adjusted for
multiple comparisons using statsmodels.sandbox.stats.multicomp.multipletests to
apply step-down Holm-Bonferroni p-value adjustments. The p-value adjustment
was performed on the whole data set simultaneously, including the mutations
presented in Supplementary Figs. 6–8. All ﬁgures show mean ± SEM.
Molecular modeling and dynamic stimulations. The soluble WT AMPA fragment was built from structure PDB ID 3KG259. Missing atoms were added with
DeepView - Swiss-PdbViewer 4.160 and removed its transmembrane fragment
514–617 and 789–817 identiﬁed with PPM server http://opm.phar.umich.edu. The
resulting model (comprising fragments 10–513 and 618–788) was minimized, then
placed in a cubic box with a water layer of 0.7 nm and Na+ Cl− ions to neutralize
the system, and a second minimization was performed. The resulting structure was
then employed as a template ad was mutated to obtain all the constructs using the
software Coot61 for mutation, rotamer manual selection and regularization of the
backbone. All models were subsequently minimized, placed once again in a cubic
box with a water layer of 0.7 nm and Na + Cl− ions to neutralize the system, and a
second minimization was performed. In all cases we used AMBER99SB-ILDN62
force ﬁeld and Simple Point Charge water. On all systems we performed NVP and
NPT equilibrations for 100 ps, followed by 30 ns NPT production run at 300 K. The
temperature was controlled with a modiﬁed Berendsen thermostat63, the pressure
with an isotropic Parrinello-Rahman at 1 bar. The iteration time step was set to 2 fs
with the Verlet integrator and LINCS constraint64. We used periodic boundary
conditions. Conﬁgurations were sampled every 10 ps. All the simulations and their
analysis were run as implemented in the GROMACS package65. Figures showing
details of the molecular structures of AMPA GLU and its mutants were made with
PyMOL (www.pymol.org). To compare the structural mobility of GluA2 and its
mutants we built a model of each protein ectodomain including LBD and ATD by
modeling mutations on the wild-type and followed their behavior along time by
means of atomistic molecular dynamics simulations in water solvent. Proteins with
mutations in the pore region where omitted as either the mutations were close to or
included in the TMDs which were not modeled.
URLs. For Interactive bio-software, see https://www.interactive-biosoftware.com/
doc/alamut-visual; for CADD, see http://cadd.gs.washington.edu/; for ClustalX, see
http:// www.ebi.ac.uk/Tools/msa/clustalw2/; for Exome Variant Server of the
National Heart, Lung, and Blood Institute Grand Opportunity (NHLBI GO)
Exome Sequencing Project (accessed February 2014), see http://evs.gs.washington.
edu/EVS/; for Genome Analysis Toolkit (GATK), see http://www.broadinstitute.
org/gatk/; for GenotypeTissue Expression (GTEx) Project, see http://www.
gtexportal.org/; for NCBI ClinVar database, see http://www.ncbi.nlm.nih.gov/
clinvar/; for Online Mendelian Inheritance in Man (OMIM), see http://omim.org/;
for Picard, see http://broadinstitute.github.io/ picard/; Primer-BLAST, http://www.
ncbi.nlm.nih.gov/tools/primerblast/; for UCSC Genome Browser, see http://
genome.ucsc.edu/; for UniProt database, see http://www.uniprot.org/; for Exome
Variant Server, see evs.gs.washington.edu/; for Ensembl, see https://www.ensembl.
org/; for GnomAD, see http://gnomad.broadinstitute.org/; for GTEx, see https://
www.gtexportal.org/home/; for Exome Aggregation Consortium (ExAC), see www.
exac.broadinstitute.org; for LOVD, see https://www.lovd.nl.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.

Data availability
The authors declare that all the data supporting the ﬁndings of this study are included in
the article (or in the Supplementary material) and available from the corresponding
author (H.H.). The source data underlying Figs. 3, 4, 5, 6, and 7 are provided as Source
Data ﬁles (https://ﬁgshare.com/s/9bd6a3ebb2f304d31b59). Data of mutations reported
within this study have been deposited in Leiden Open Variation Database (accession
numbers for the DNA sequences: 00231337; 00231345; 00231346; 00231347; 00231348;
00231349; 00231388; 00231389; 00231356; 00231359; 00231362; 00231363; 00231365;
00231366; 00231368; 00231369; 00231371; 00231372; 00231376; 00231377; 00231378;
00231379; 00231380; 00231381).
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